In most pharmaceutical markets, biologics and targeted therapies are expected to dominate the drug type segment due to their higher efficacy, specificity, and ability to address complex diseases such as cancer, autoimmune disorders, and chronic conditions. Biologics, including monoclonal antibodies and cell-based therapies, are seeing strong adoption as they offer personalized treatment options with fewer side effects compared to traditional small-molecule drugs. Meanwhile, targeted therapies are gaining traction because they focus on disease pathways at a molecular level, improving patient outcomes. This shift is further supported by rising R&D investments, regulatory approvals, and growing demand for precision medicine.
